Partisanship and anti-elite worldviews as correlates of science and health beliefs in the multi-party system of Spain.

In a national sample of 5087 Spaniards, we examine the prevalence of 10 specific misperceptions over five separate science and health domains (climate change, 5G technology, genetically modified foods, vaccines, and homeopathy). We find that misperceptions about genetically modified foods and general health risks of 5G technology are particularly widespread. While we find that partisan affiliation is not strongly associated with any of the misperceptions aside from climate change, we find that two distinct dimensions of an anti-elite worldview-anti-expert and conspiratorial mindsets-are better overall predictors of having science and health misperceptions in the Spanish context. These findings help extend our understanding of polarization around science beyond the most common contexts (e.g. the United States) and support recent work suggesting anti-elite sentiments are among the most important predictors of factual misperceptions.

Correction to: A four-step mutation at D22S1045 in one complex paternity case when the brother of the alleged father hypothesis is evaluated.

This article was published online with an error. Given names and family names of the authors were interchanged. The correct author names are presented above. The original article has been corrected.

A four-step mutation at D22S1045 in one complex paternity case when the brother of the alleged father hypothesis is evaluated.

We report one complex paternity case presenting a presumable paternal four-step STR mutation between the alleged father (AF) and child; the complexity of the case required the AF-brother hypothesis to be discarded without including this DNA sample. A total of 23 autosomal STR loci included in the Powerplex Fusion® and Globalfiler™ kits confirmed one isolated mismatch for D22S1045 between the AF (17/17) and the male child (13/15) in the presence of the mother (15/15). In this case, the STR structure and father's age do not seem to have contributed to promote the observed multistep mutation. The Paternity Index (PI) based on 23 autosomal STRs did not favor the AF paternity over the AF-brother hypothesis based on a flat prior (PI = 0.1217; W = 10.85%). For that reason, we included 38 autosomal human identification (HID) insertions-deletions (indels) and 20 retrotransposon insertion polymorphisms (RIPs) contained in the InnoTyper® 21 kit. Although these biallelic markers favored the AF paternity rather than the AF-brother hypothesis (LR = 110.3; W = 99.1%), the global PI based on 81 autosomal markers supported moderately the AF paternity hypothesis (LR = 13.4; W = 93.1%). The application of different mutation models showed a consistent support to the AF paternity hypothesis (PI = 93.1-99.95%), which could be useful for interpretation in these multistep STR mutation cases. In brief, we showed the impact of a four-step mutation at D22S1045 to obtain definitive paternity conclusions, particularly under a complex scenario when the AF-brother hypothesis is assessed. Forensic genomics arises as the next option for similar complex paternity cases.

Determinación de mutaciones (del E746-A750 exón 19 y L858R exón 21) en el gen receptor del factor de crecimiento epidérmico (EGFR) en muestras de suero y biopsia de carcinoma pulmonar no microcítico (CPNM) / Determination of mutations (del E746-A750 exon 19 and L858R exon 21) in the epidermal growth factor receptor (EGFR) gene in serum samples and in biopsys of non-microcytic lung carcinoma (NMLC)

Resumen Introducción Las mutaciones, del E746-A750 exón 19 y L858R exón 21 del gen EGFR en células tumorales de CPNM representan biomarcadores de respuesta a fármacos inhibidores de tirosina cinasa (ITK). Pacientes con tumores positivos a mutaciones EGFR muestran mejor respuesta y mayor sobrevivencia. Estas mutaciones ocupan el 90% de las mutaciones en cáncer de pulmón. Objetivo Evaluar la frecuencia de las mutaciones del E746-A750 exón 19 y L858R exón 21 del EGFR en muestras de biopsia de CPNM y en muestras de suero de población abierta de Yucatán. Material y métodos Se seleccionaron 19 muestras de biopsia de CNPM tipo adeconocarcinoma y 101 sueros de sujetos sanos. Las mutaciones del E746-A750 y L858R en EGFR se determinaron mediante amplificación por PCR oligo-alelo específica (PCR-ASO). Se calcularon las frecuencias genotípicas y alélicas y su distribución según Hardy Weinberg, utilizando la plataforma SNPstats. Resultados En muestras de suero se determinó el genotipo homocigoto (1/1) en 26.58%, 73.42% el heterocigoto (1/0) y ausencia del genotipo mutante con deleción (0/0) para del E746-A750; en tanto que, para L858R, 21.78% resultó homocigoto (TT), 54.46% heterocigoto (T/G) y 23.76% mutantes GG. En las biopsias, el heterocigoto fue más frecuente en ambas mutaciones 63.16% y 73.68% para del E746-A750 y L858R, respectivamente. Conclusión. La frecuencia de las mutaciones del gen EGFR en las muestras de sueros fue de 36.71% para la deleción del E746-A750 en exón 19 y 50.99% para L858R en exón 21. La distribución de las mutaciones en muestras de biopsia CPNM resultó en 42.11% para cada mutación estudiada.

Abstract Introduction EGFR mutations, del E746-A750 in exon 19 and L858R in exon 21 in tumor cells of NMLC represent biomarkers of response to tyrosine kinase inhibitors (TKI) therapy. Patients with tumors positive for EGFR mutations show better response and greater survival. These mutations occupy 90% of mutations in lung cancer. Objective To evaluate the frequency of mutations del E746-A750-exon 19 and L858R-exon 21 of EGFR gene in NMLC biopsy samples and in serum samples of the general population from Yucatán. Material and methods 19 NMLC biopsy samples of adenocarcinoma type and 101 serum samples from healthy subjects were selected. EGFR mutations del E746-A750 and L858R were determined by allele-specific PCR amplification (PCR-ASO). The genotypic and allelic frequencies; and their distribution according to Hardy Weinberg expectations were calculated using the SNPstats software. Results For serum, EGFR del E746-A750 mutation, homozygous genotype (1/1) was present in 26.58%, heterozygote (1/0) in 73.42% and absence of mutant genotype with deletion (0/0); whereas for L858R mutation, 21.78% were homozygous (TT), 54.46% heterozygous (T/G) and 23.76% GG mutants. For the NMLC biopsies, the heterozygote was the most frequent genotype for both mutations, 63.16% and 73.68% for del E746-A750 and L858R, respectively. Conclusion The frequency of mutations of EGFR gene in serum samples was 36.71% for deletion delE746-A750 in exon 19 and 50.99% for L858R in exon 21. Distribution of mutations in biopsy samples NMLC resulted in 42.11% for each EGFR mutation.